iX Biopharma Ratios and Metrics

Market cap in millions SGD. Fiscal year is July - June.

Millions SGD. Fiscal year is Jul - Jun.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Sep '25 Sep 18, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	2016 - 2020
Market Capitalization	17	14	22	70	122	167	Upgrade
Market Cap Growth	-36.24%	-36.24%	-68.05%	-43.05%	-26.84%	3.17%	Upgrade
Enterprise Value	22	17	22	62	111	162	Upgrade
PS Ratio	2.17	1.83	3.74	11.79	8.51	95.91	Upgrade
PB Ratio	46.22	38.92	5.13	4.40	6.20	14.29	Upgrade
P/TBV Ratio	177.59	149.55	5.51	4.48	6.31	14.81	Upgrade
P/FCF Ratio	-	-	-	-	41.89	-	Upgrade
P/OCF Ratio	-	-	-	-	39.21	-	Upgrade
EV/Sales Ratio	2.82	2.20	3.73	10.51	7.70	92.74	Upgrade
EV/EBITDA Ratio	-	-	-	-	96.40	-	Upgrade
EV/EBIT Ratio	-	-	-	-	221.09	-	Upgrade
EV/FCF Ratio	-5.53	-	-	-	37.89	-	Upgrade
Debt / Equity Ratio	16.17	16.17	1.20	0.27	0.22	0.36	Upgrade
Debt / EBITDA Ratio	-	-	-	-	2.91	-	Upgrade
Debt / FCF Ratio	-	-	-	-	1.51	-	Upgrade
Asset Turnover	0.60	0.60	0.30	0.22	0.61	0.10	Upgrade
Inventory Turnover	4.98	4.98	4.21	3.86	2.09	2.14	Upgrade
Quick Ratio	0.31	0.31	0.65	1.34	1.98	2.19	Upgrade
Current Ratio	0.47	0.47	0.89	1.53	2.14	2.55	Upgrade
Return on Equity (ROE)	-431.07%	-431.07%	-106.91%	-54.02%	-29.23%	-75.27%	Upgrade
Return on Assets (ROA)	-30.32%	-30.32%	-23.69%	-22.32%	1.32%	-39.86%	Upgrade
Return on Capital (ROIC)	-49.70%	-49.70%	-31.51%	-26.91%	1.56%	-47.57%	Upgrade
Return on Capital Employed (ROCE)	-	-	-	-	2.40%	-	Upgrade
Earnings Yield	-60.11%	-71.38%	-48.44%	-13.79%	-3.75%	-4.92%	Upgrade
FCF Yield	-23.47%	-27.87%	-30.64%	-11.98%	2.39%	-5.32%	Upgrade
Buyback Yield / Dilution	-14.25%	-14.25%	-0.33%	-2.51%	-7.60%	-7.13%	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.